MedTrace Logo

Tributyrin to Promote Gut Health Among Children Undergoing Hematopoietic Cell Transplantation

NCT05951153 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2024-08-15

No results posted yet for this study

Summary

To determine the safety and tolerability of tributyrin among children undergoing hematopoietic cell transplantation (HCT).

Conditions

  • Hematopoietic Cell Transplantation (HCT)

Interventions

COMBINATION_PRODUCT

Tributyrin

Tributyrin is a nutritional supplement prepared by esterification of glycerin with butyric acid that promotes delivery of free butyrate to distal portions of the gut.

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-01
Primary Completion
2025-11-30
Completion
2026-11-30
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05951153 on ClinicalTrials.gov